Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 7/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 5/20 | 0.45 |
| ▸ | MAOA | P21397 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | SDHA | P31040 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5763614 | 1.00 | CALML3 (0.47) | CALML3F10MAOBMAOALMNA | |
| SCHEMBL6686605 | 0.88 | F10 (0.57) | CALML3F10MAOBMAOALMNA | |
| SCHEMBL2891483 | 0.87 | MAOA (0.46) | CALML3F10MAOBMAOALMNA | |
| SCHEMBL1556212 | 0.84 | CALML3 (0.45) | CALML3F10MAOBMAOALMNA | |
| SCHEMBL1557789 | 0.84 | CALML3 (0.45) | CALML3F10MAOBMAOALMNA | |
| SCHEMBL9823484 | 0.83 | GRM2 (0.50) | F10GRM2 | |
| SCHEMBL1394138 | 0.83 | F10 (0.52) | CALML3F10MAOBMAOALMNA | |
| SCHEMBL5917588 | 0.83 | F10 (0.52) | CALML3F10MAOBMAOALMNA | |
| SCHEMBL1036374 | 0.83 | F10 (0.52) | CALML3F10MAOBMAOALMNA | |
| SCHEMBL1035579 | 0.83 | CALML3 (0.65) | CALML3MAOBMAOALMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-11 | — | — | US | disclosed |
| EP-1799677-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | Ranbaxy Laboratories Limited (IN) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006038100-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-13 | — | — | WO | disclosed |
| US-6689779-B2 | PYRIDINE OR PYRIMIDINE SUBSTITUTED; ANTIBACTERIAL ACTIVITY; LOW TOXICITY | DONG A PHARM. CO., LTD. (KR) | 2004-02-10 | — | — | US | disclosed |
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | DONG A PHARM. CO., LTD. (KR) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | OXA1L, ODC1, PDCD4 | CALML3 4610/4885F10 2544/4885MAOB 593/4885 |
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | OXA1L, PDK4, MLYCD | CALML3 3047/4885F10 1709/4885MAOB 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.